Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis
暂无分享,去创建一个
P. Hainaut | S. Sangrajrang | Doriane A. Gouas | J. Groopman | S. Villar | A. Plymoth | T. Khuhaprema | B. Abedi-Ardekani | M. Friesen | A. Nogueira da Costa | S. Ortiz-Cuaran | A. Kalalak
[1] H. Whittle,et al. Seasonal Variation in TP53 R249S-Mutated Serum DNA with Aflatoxin Exposure and Hepatitis B Virus Infection , 2011, Environmental health perspectives.
[2] P. Hainaut,et al. Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand , 2011, Hepatitis research and treatment.
[3] G. Leroux-Roels,et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region , 2011, Journal of viral hepatitis.
[4] H. Whittle,et al. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[5] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[6] Hai-rim Shin,et al. Epidemiology of cholangiocarcinoma: An update focusing on risk factors , 2010, Cancer science.
[7] Yan Liu,et al. Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment , 2010, Environmental health perspectives.
[8] P. Hainaut,et al. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. , 2009, Cancer letters.
[9] P. Hainaut,et al. In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. , 2009, Gastroenterology.
[10] K. Straif,et al. A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.
[11] P. Vineis,et al. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. , 2007, Mutation research.
[12] Douglas L. Park,et al. Workgroup Report: Public Health Strategies for Reducing Aflatoxin Exposure in Developing Countries , 2006, Environmental health perspectives.
[13] J. Goedert,et al. Quantitative Analysis of Plasma TP53 249Ser-Mutated DNA by Electrospray Ionization Mass Spectrometry , 2005, Cancer Epidemiology Biomarkers & Prevention.
[14] N. Maneekarn,et al. Hepatitis B 1762T/1764A Mutations, Hepatitis C Infection, and Codon 249 p53 Mutations in Hepatocellular Carcinomas from Thailand , 2005, Cancer Epidemiology Biomarkers & Prevention.
[15] H. Sriplung,et al. Epidemiology of liver cancer: an overview. , 2004, Asian Pacific journal of cancer prevention : APJCP.
[16] T. Yoshizawa,et al. In-house direct cELISA for determining aflatoxin B 1 in Thai corn and peanuts , 2003, Food additives and contaminants.
[17] B. Stewart,et al. World Cancer Report , 2003 .
[18] Leslie T. Stayner,et al. IARC Monographs on the evaluation of carcinogenic risks to humans: Some traditional herbal medicines, some mycotoxins, naphthalene and styrene , 2002 .
[19] M. Feitelson,et al. Genetic mechanisms of hepatocarcinogenesis , 2002, Oncogene.
[20] S. Chunsuttiwat,et al. Impact of hepatitis B immunisation as part of the EPI. , 2000, Vaccine.
[21] G. Meijer. GLOBOCAN 1: Cancer Incidence and Mortality Worldwide. , 2000 .
[22] C. Wild,et al. Liver cancer in Thailand. II. A case‐control study of hepatocellular carcinoma , 1991, International journal of cancer.
[23] C. Wild,et al. Mycotoxins and Human Disease: a Largely Ignored Global Health Issue , 2022 .
[24] J. Groopman,et al. Aflatoxin and hepatitis B virus biomarkers: a paradigm for complex environmental exposures and cancer risk. , 2005, Cancer biomarkers : section A of Disease markers.
[25] Iarc Monographs,et al. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. , 2002, IARC monographs on the evaluation of carcinogenic risks to humans.
[26] J. Goedert,et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. , 2000, Journal of the National Cancer Institute.
[27] E. Somers. International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.